Table 1.
Patient Demographics and Outcomes of Late Chronic Infections Under Suppressive Antimicrobial Therapy With Tedizolid
| Patient ID | Sex | Age at Infection, y | BMI, kg/m2 | ASA Score | Concomitant Drug Administrationa | Site of Infection | Type of Surgery | Pathogens | LZD AE | Days of LZD Prior to Switch to TZD | Duration of TZD, mo (d) | Reason for Stopping TZD | TZD AE | Follow-up duration, mo (d) | Outcome |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | M | 71 | 27.8 | 1 | Amitriptyline, tramadol | Knee PJI | DAIR | MRSE | NA | NA | 31 (960) | NA | None | 38 (1168) | Infection controlled |
| 2 | M | 86 | 22.0 | 3 | None | Knee PJI | No surgery (inextirpable implant) | History of various pathogens infection (Helcococcus kunzii, Enterococcus faecalis, MSSA, Corynebacterium striatum, Proteus mirabilis, Escherichia coli) | NA | NA | 6 (210) | Persistent discharge, uncontrolled infection. TZD stopped as a consequence of a serious AE (seizure) due to ertapenem (concomitant administration) | None | 9 (281) | Failure |
| 3 | M | 79 | 26.8 | 2 | Tramadol | Knee PJI | DAIR | No growth (history of MRSE infection) | Diarrhea Asthenia |
29 | 16 (516) | Persistent discharge, pain, positive culture despite SAT | None | 17 (545) | Failure |
| 4 | M | 82 | 28.9 | 3 | Tramadol | Knee PJI | DAIR | MRSE | Thrombopenia (63 x 109/L) | 19 | 17 (540) | NA | None | 18 (559) | Infection controlled |
| 5 | M | 74 | 26.6 | 2 | None | Hip PJI | DAIR with ceramic head exchange | MRSE | Anemia (6.9 g/dL) | 28 | 2 (61) | New PJI | None | 5 (153) | Failure |
| 6 | M | 64 | 29.4 | 2 | None | Knee PJI | DAIR | MSSE Staphylococcus hominis (MS) (history of MRSE infection) |
NA | NA | 14 (441) | NA | None | 17 (524) | Infection controlled |
| 7 | M | 71 | 28.4 | 2 | None | Knee PJI | Arthrodesis | MRSE | None | 28 | 6 (190) | NA | None | 7 (243) | Infection controlled |
| 8 | M | 69 | 32.0 | 2 | None | Hip PJI | DAIR | MRSE Pseudomonas aeruginosa |
None | 35 | 5 (175) | NA | None | 8 (256) | Infection controlled |
| 9 | F | 89 | 20.3 | 2 | None | Knee PJI | DAIR | MRSE | Neutropenia | 14 | 21 (645) | NA | None | 21 (659) | Small fistulab |
| 10 | F | 87 | 34.2 | 3 | None | Knee PJI | DAIR | MRSE | Thrombopenia (16 x 109/L) | 24 | 8 (244) | NA | None | 8 (269) | Small fistulab |
| 11 | M | 81 | 36.1 | 3 | None | Shoulder PJI | DAIR | MSSA (history of MRSE infection) |
Anemia (8.6 g/dL) Thrombopenia (103 x 109/L) |
5 | 15 (483) | NA | None | 15 (488) | Infection controlled |
| 12 | F | 24 | 19.5 | 2 | None | Femoral intramedullary nail | Nail exchange |
Staphylococcus capitis Enterococcus faecium (VR) |
Anemia (6.9 g/dL) | 56 | 13 (423) | NA | None | 16 (498) | Infection controlled |
| 13 | F | 70 | 28.4 | 2 | Amitriptyline | Hip PJI | DAIR | MSSE C striatum (PCR) |
Anemia (8.1 g/dL) Thrombopenia (131 x 109/L) |
20 | 6 (212) | NA | None | 7 (236) | Infection controlled |
| 14 | M | 67 | 22.5 | 2 | None | Hip PJI | 1-stage exchange | MRSE MSSA P mirabillis |
Thrombopenia (75 x 109/L) | 28 | 2 (87) | NA | None | 5 (157) | Infection controlled |
| 15 | M | 77 | 31.1 | 2 | None | Knee PJI | DAIR | Staphylococcus caprae (MR) (history of MSSA, S capitis [MR] infection) | None | 14 | 1 (35) | Persistent discharge, uncontrolled infection | None | 2 (78) | Failure |
| 16 | M | 54 | 36.7 | 2 | None | Hip PJI | DAIR | MRSE (history of MRSA) | None | 14 | 1 (36) | NA | None | 3 (93) | Infection controlled |
| 17 | M | 73 | 27.1 | 3 | Tramadol | Knee PJI | DAIR | C striatum | NA | NA | 1 (50) | NA | None | 3 (97) | Infection controlled |
Abbreviations: AE, adverse event; ASA, American Society of Anesthesiologists; BMI, body mass index; DAIR, debridement, antibiotic, implant retention; F, female; ID, identifier; LZD, linezolid; M, male; MR, methicillin-resistant; MRSA, methicillin-resistant Staphylococcus aureus; MRSE, methicillin-resistant Staphylococcus epidermidis; MS, methicillin-susceptible; MSSA, methicillin-susceptible Staphylococcus aureus; MSSE, methicillin-susceptible Staphylococcus epidermidis; NA, not applicable; PCR, polymerase chain reaction; PJI, periprosthetic joint infection; SAT, suppressive antimicrobial therapy; TZD, tedizolid; VR, vancomycin-resistant.
aOnly considered drugs with potential drug–drug interactions with oxazolidinones: tricyclic antidepressant, selective serotonin reuptake inhibitors, and tramadol. No other drugs with potential interaction were prescribed to patients.
bThese 2 patients were not considered as having failed treatment (see text).